These KLHL14 mutations occurred frequently and were recently found to confer resistance to ibrutinib in ABD-DLBCL by promoting the assembly of MYD88-TLR9-BCR (My-T-BCR) supercomplex [22]. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.